Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS41963
• Study ID:
  46244
• Official title and acronym:
  Registry of Asthma Patients Initiating DUPIXENT® (RAPID)
• DARWIN EU® study:
  No
• Study countries:
  Canada

  Denmark

  France

  Italy

  Japan

  Puerto Rico

  Spain

  Sweden

  United Kingdom

  United States
• Study description:
  The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: • Patient demographics (eg, gender, age, and race) • Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: • To characterize real-world use patterns of DUPIXENT® for asthma • To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting • To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® • To collect long-term safety data on study participants in the real-world setting
• Study status:
  Ongoing

Research institutions and networks

Institutions

Regeneron Pharmaceuticals

Study timelines

Date when funding contract was signed

Actual:26/09/2019

Study start date

Actual:02/03/2020

Data analysis start date

Planned:10/06/2026

Actual:09/06/2026

Date of final study report

Planned:09/06/2027

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

Regeneron Pharmaceuticals, Inc., Sanofi (Collaborator)

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

R668-AS-1885,NCT04287621